Glomerulus
Nephrotic Syndrome
search
Nephrotic Syndrome
, Nephrosis
Definition
Conditions causing
Proteinuria
, edema, hypoalbuminemia and
Hyperlipidemia
Epidemiology
Incidence
: 3 per 100,000 per year in U.S.
Pathophysiology
Edema
in Nephrotic Syndrome
Underfill mechanism (children)
Significant
Proteinuria
results in hypoalbuminemia
Decreased oncotic pressure results in edema
Overfill mechanism (adults)
Glomerulus becomes more permeable to albumin and other
Protein
s
Proteinuria Causes
tubulointerstitial inflammation
Hypoalbuminemia also occurs and results in decreased oncotic pressure
Sodium
retention leads to edema
Types
Histologic
Primary glomerulonephropathy progresses to Nephrosis
Occurs in 20% of cases
Children
Minimal Change Disease
(
NIL Lesion
)
Adults
Membranous Nephropathy
(33%)
Most common in white patients
Focal Segmental Glomerulosclerosis
(33%)
Most common in black patients
Minimal Change Disease
(15%)
Immunoglobulin A
Nephropathy (15%)
Causes
Secondary
Idiopathic (80-90% of cases)
Most common
Systemic Lupus Erythematosus
Diabetic glomerulosclerosis in
Diabetes Mellitus
Immunologic and metabolic
Cryoglobulinemia
Goodpasture's Syndrome
(anti-Glomerular Basement Membrane Disease)
Henoch Schonlein Purpura
Polyarteritis Nodosa
Sjogren Syndrome
Membranoproliferative
Glomerulonephritis
(MPGN)
IgA Nephropathy
Amyloidosis
Erythema Multiforme
Microscopic polyangitis
Viral Infection
Hepatitis B
Infection
Hepatitis C
Infection
HIV Infection
Epstein-Barr Virus
(
Mononucleosis
)
Herpes Zoster
(
Shingles
)
Bacterial Infection
Infective Endocarditis
Syphilis
Leposy
Protozoa
Infection
Filariasis
Helminthiasis
Malaria
Schistosomiasis
Malignancy
Multiple Myeloma
Melanoma
Leukemia
or
Lymphoma
(e.g.
Hodgkin's Lymphoma
)
Other cancers (e.g.
Lung Cancer
,
Breast Cancer
,
Colon Cancer
,
Renal Cell Carcinoma
)
Medications and drugs
NSAID
s
Penicillamine
Gold
Lithium
Heroin
Pamidronate
Interferon alfa
Mercury Poisoning
Miscellaneous
Preeclampsia
or
Eclampsia
Alport Syndrome
Allergic Reaction
(e.g.
Insect
stings,
Snake Bite
, anti-toxins,
Poison Ivy
)
Malignant Hypertension
Sarcoidosis
Castleman Disease
Symptoms
Edema
(see signs below) with secondary weight gain
Foamy urine
Exertional
Dyspnea
Fatigue
Signs
Hypertension
Edema
(most common presenting complaint)
Initial: Progressive
Lower Extremity Edema
Later: Periorbital edema,
Scrotal Edema
,
Pleural Effusion
,
Ascites
May present with acute
Congestive Heart Failure
Labs
Diagnosis
Diagnostic criteria (in combination with edema)
Hypoalbuminemia (
Serum Albumin
<2.5 g/dl)
Hyperalbuminuria (
Proteinuria
>3.0 to 3.5 grams per day)
Other associated lab findings (supportive, but not required for diagnosis)
Hyperlipidemia
(
Total Cholesterol
often >300 to 350 mg/dl)
Urinalysis
Urine Dipstick
with 3+
Protein
suggests nephrotic range
Proteinuria
Use only for initial screening and then confirm with
Urine Protein to Creatinine Ratio
Hematuria
or casts suggests
Glomerulonephritis
Urine Protein to Creatinine Ratio
Ratio >3 to 3.5 suggests nephrotic range
Proteinuria
Correlates with 3 to 3.5 grams
Protein
in
24 Hour Urine Protein
Efficacy is equivalent to a
24 Hour Urine Protein
collection
Lipid
profile
Total Cholesterol
>300 mg/dl (>50% of patients with Nephrotic Syndrome)
Comprehensive metabolic panel
Serum Albumin
<2.5 g/dl
Serum Creatinine
increase and GFR reduced in some cases
However
Acute Kidney Injury
from Nephrotic Syndrome is uncommon
Other findings
Increased serum transaminases may suggest underlying
Viral Hepatitis
Renal Biopsy
Defer decision to biopsy to nephrology
Indications
Often not needed if controlled disease or secondary cause is known
Useful in cases in which biopsy would direct treatment or inform prognosis
Idiopathic cases or unknown histologic type
Renal disorders (e.g. SLE)
Severe disease or
Corticosteroid
refractory
Labs
Initial Evaluation of Causes to consider
HIV Test
Hepatitis B Serology
(
HBsAg
)
Hepatitis C Serology
(
Hepatitis C
Antibiody, xHCV)
Serum Protein Electrophoresis
or
Urine Protein
electrophoresis (
Multiple Myeloma
,
Amyloidosis
)
Rapid Plasma Reagin
(
Syphilis
)
Connective tissue labs
Antinuclear Antibody
Anti-dsDNA
Complement C3
Complement C4
Imaging
Renal
Ultrasound
Indicated in reduced GFR
Other imaging to consider in evaluation of complications or differential diagnosis of edema
Chest XRay
Echocardiogram
Abdominal Ultrasound
Differential Diagnosis
See
Edema
See
Glomerulonephritis
See
Acute Kidney Injury
Acute Interstitial Nephritis
Acute Tubular Necrosis
Renal Vein Thrombosis
Management
Consult with nephrology
Test for underlying cause (often idiopathic)
Fluids and
Electrolyte
s
Limit daily
Sodium
intake to 3 grams/day
Consider limiting oral fluids to <1.5 Liters daily
Diuretic
s
Precautions
Initial goal weight loss: 2-4 lb (1 to 2 kg) per day
Later goal weight loss: 1-2 lb (0.5 to 1 kg) per day (risk of
Acute Renal Failure
if excessive)
Loop Diuretic
s (e.g.
Furosemide
)
Diuretic
resistance is typical (due to
Protein
-bound nature of
Diuretic
s and hypoalbuminemia)
Often requires high dose (e.g.
Furosemide
80 to 120 mg)
May require IV dosing as oral absorption may be reduced due to intestinal edema
Consider human albumin 20% IV before IV
Diuretic
dose (acute cases only)
Starting doses
Furosemide
40 mg orally twice daily OR
Bumetanide
1 mg twice daily
Dose titration
Double dose every 1-3 days until adequate effect
Adjunctive
Diuretic
s
Thiazide Diuretic
s
Spironolactone
Metolazone
(
Zaroxolyn
)
ACE Inhibitor
(or
Angiotensin Receptor Blocker
if
ACE Inhibitor
intolerant)
Typically recommended to reduce
Proteinuria
even if normotensive
Enalapril
(
Vasotec
) 2.5 to 20 mg per day (dosing used in studies)
Lisinopril
Corticosteroid
s
Example protocol (adult dosing)
Prednisone
60 mg daily for 4 weeks, then 40 mg every other day for 4 weeks
Hahn (2015) Cochrane Database Syst Rev (3):CD001533 [PubMed]
Minimal Change Disease
(especially in children)
Corticosteroid
responsive
Focal Glomerulosclerosis
and
Membranous Nephropathy
Variable response to
Corticosteroid
s
Management per local consultant recommendations
Immunosuppressant
s (e.g.
Cyclophosphamide
,
Chlorambucil
,
Cyclosporine
,
Rituximab
)
Used alone or in combination with
Corticosteroid
s in some cases (steroids ineffective, intolerable)
Immunosuppressant
s may be very effective in some secondary causes (e.g. SLE)
Other measures
Avoid
Nephrotoxin
s (e.g.
NSAID
s)
Maintain
Blood Pressure
less than 130/80
Control
Hyperlipidemia
Also improves as
Proteinuria
resolves and underlying secondary cause improves
Other measures that may be considered in specific cases
Prophylactic
Anticoagulation
Consider in superimposed
Hypercoagulable
states (but not used in most cases)
Avoid unproven strategies
Avoid intravenous albumin
Avoid prophylactic
Antibiotic
s
Complications
Venous Thromboembolism
(
Deep Vein Thrombosis
and
Pulmonary Embolism
)
Relative Risk
of 1.4 to 1.7
Deep Vein Thrombosis
(occurs in 1.5% of adult Nephrotic Syndrome)
Renal vein thrombosis (occurs in 0.5% of adult Nephrotic Syndrome)
Results in part from loss of coagulation regulatory
Protein
s (
Protein
C and
Protein
S)
Risk factors
Age 18 to 39 years
Nephrotic Syndrome onset in last 6 months
Membranous Nephropathy
as the cause of Nephrotic Syndrome (occurs in 7% of cases)
Serum Albumin
<2.0 to 2.5 g/dl
Infection and
Immunodeficiency
Mechanism
Serum IgG and complement loss (
Proteinuria
)
Nephrotic Syndrome management (
Corticosteroid
s)
Risk factors
Children
Nephrotic Syndrome relapse
Corticosteroid
use
Most common infections
Cellulitis
Peritonitis
Sepsis
Acute Renal Failure
Rare complication
Appears to be multifactorial
Sepsis
Excessive diuresis
Renal vein thrombosis
Renal
Interstitial Edema
Prognosis
Variable based on histology and secondary cause
Idiopathic
Membranous Nephropathy
One third with benign course
One third with persistent
Proteinuria
or edema but normal
Renal Function
One third with progression to
End Stage Renal Disease
(
ESRD
) within 10 day
Chen (2014) Cochrane Database Syst Rev (10):CD004293 [PubMed]
Primary focal segmental sclerosis
Moderate
Proteinuria
(3 g/day):
ESRD
develops in 50% over 5-10 years
Severe
Proteinuria
(>10 g/day):
ESRD
develops within 3-5 years
Korbet (2012) J Am Soc Nephrol 23(11): 1769-76 [PubMed]
References
Hull (2008) BMJ 336(7654): 1185-9 [PubMed]
Karnath (2007) Hosp Physician 43(10): 25-30 [PubMed]
Kodner (2009) Am Fam Physician 80(10): 1129-36 [PubMed]
Kodner (2016) Am Fam Physician 93(6):479-85 [PubMed]
Type your search phrase here